Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with Biologic therapies

Journal of Rheumatology

Volumn 41, Issue 8, 2014, Pages 1600-1606

  Barnabe, Cheryl ^a,b   Thanh, Nguyen Xuan ^c,d   Ohinmaa, Arto ^c,d   Homik, Joanne ^d   Barr, Susan G ^a,b   Martin, Liam ^a   Maksymowych, Walter P ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biologics; Healthcare costs; Outcome assessment; Remission definitions; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL DISEASE ACTIVITY INDEX; COMORBIDITY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT INDICATION;

EID: 84905507213     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131449     Document Type: Article

References (27)

1. Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 2011;25:607-24.
2. Jobanputra P. A clinician's critique of rheumatoid arthritis health economic models. Rheumatology 2011;50 Suppl 4:iv48-iv52.
3. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006;24 Suppl 43:S-29-32.
4. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
5. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-iv, xi-xiii, 1-229.
6. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-αlpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46:1345-54.
7. Lekander I, Borgstrom F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P, et al. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ 2013;14:863-73.
8. Virkki LM, Konttinen YT, Peltomaa R, Suontama K, Saario R, Immonen K, et al. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2008;26:1059-66.
9. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57.
10. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
11. Thiele K, Huscher D, Bischoff S, Spathling-Mestekemper S, Backhaus M, Aringer M, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1194-9.
12. Fujiwara M, Kita Y. Reexamination of the assessment criteria for rheumatoid arthritis disease activity based on comparison of the Disease Activity Score 28 with other simpler assessment methods. Mod Rheumatol 2013;23:260-8.
13. Michaud K, Mikuls TR, Call SE, Reimold AM, Hooker R, Kerr GS, et al. Poor to modest agreement between rheumatoid arthritis response measures in clinical practice. Clin Exp Rheumatol 2009;27:633-40.
14. Barnabe C, Thanh NX, Ohinmaa A, Homik J, Barr SG, Martin L, et al. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis 2013;72:1664-8.
15. Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol 2007;36:179-83.
16. Barr SG, Martin L, Chung C, Maksymowych WP. Mandatory pharmacosurveillance - A Canadian model for access to therapy and research. Clin Exp Rheumatol 2004;22 Suppl 35:S39-43.
17. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
18. Dehejia R, Wahba S. Propensity score matching methods for nonexperimental causal studies. Rev Economics Statistics 2002;84:151-61.
19. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
20. Becker S, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J 2002;2:358-77.
21. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-63.
22. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res 2012;64:1811-8.
23. Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30 Suppl 73:S72-84.
24. Weycker D, Yu EB, Woolley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or = 65 years with rheumatoid arthritis. Clin Ther 2005;27:646-56.
25. McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis. J Rheumatol 2011;38:2141-9.
26. Joyce AT, Smith P, Khandker R, Melin JM, Singh A. Hidden cost of rheumatoid arthritis (RA): Estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol 2009;36:743-52.
27. de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, et al. Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria. Rheumatology 2012;51:1269-77.